ArticleTherapeutic advances in gastroenterology2026
Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: No established predictive biomarker beyond tissue HER2 status currently exists for trastuzumab deruxtecan (T-DXd) treatment response in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Serum HER2 extracellular domain (HER2 ECD) has shown potential in breast cancer; however, its clinical significance in gastric cancer remains unclear. Objectives: To evaluate the efficacy and safety of T-DXd in HER2-positive AGC and investigate the predictive role of serum HER2 ECD for T-DXd response. Design: Retrospective single-institution study. Methods: Data of HER2-positive AGC patients treated with T-DXd were analyzed. According to their baseline serum HER2 ECD levels, the patients were classified into high (⩾12.1 ng/mL) and low (<12.1 ng/mL) HER2 ECD groups. Tumor responses, HER2 ECD dynamics, HER2 re-biopsy status, progression-free survival (PFS), and overall survival (OS) were evaluated. Results: Altogether, 67 patients were enrolled. The HER2 ECD data were available only for 38 patients, with 23 and 15 patients in the high and low HER2 ECD groups, respectively. The objective response rate (ORR) was significantly higher in the high HER2 ECD group (65.2%, 15/23 vs 26.7%, 4/15; Conclusion: Baseline serum HER2 ECD may be a potential non-invasive predictor of T-DXd response in HER2-positive AGC, particularly in IHC 2+/ISH+ cases. Dynamic HER2 ECD level changes during therapy may also reflect treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.